Medication Guides and patient package inserts

Pharmacies and other dispensers hand patients roughly 506 million Medication Guides a year, by FDA's estimate. The figure appears in a July 1, 2026, Federal Register notice² seeking to reinstate the federal paperwork approval behind the guides. It assumes 88,736 authorized dispensers, each giving guides to an average of 5,705 patients a year, at about 10 seconds per handoff (0.0027 hours in FDA's table).

The rule behind those sheets of paper, 21 CFR Part 208¹, dates to a final regulation of Dec. 1, 1998. A patient picking up a prescription today may also get a patient package insert, an Instructions for Use booklet and a leaflet the pharmacy prints from a private vendor, and FDA has proposed folding much of that into a single page.

When FDA requires a Medication Guide

Part 208 applies mainly to prescription drugs used at home without a health professional's direct supervision, and it covers new prescriptions and refills alike. Under section 208.1(c)¹, FDA will require patient labeling when it finds one or more of three conditions. The drug is one "for which patient labeling could help prevent serious adverse effects." Or it has serious risks, relative to benefits, that "could affect patients' decision to use, or to continue to use, the product." Or it is "important to health and patient adherence to directions for use is crucial to the drug's effectiveness."

FDA keeps a searchable Medication Guide database⁵, and many familiar generics carry one. Labels on DailyMed⁸ checked for this article include Medication Guides for sertraline, fluoxetine, duloxetine, montelukast, warfarin, gabapentin, ciprofloxacin and meloxicam. The sertraline label in that check came from a generic maker.

What the guide must contain

Section 208.20 is unusually specific for a federal regulation. The guide must be in English, in "nontechnical, understandable language," and "shall not be promotional in tone or content." Type can be no smaller than 10 points. The words "Medication Guide" go at the top of the first page, and the bottom must carry the verbatim line "This Medication Guide has been approved by the U.S. Food and Drug Administration." The rule also fixes the order of headings, using only those relevant to the drug.

How a guide reaches the patient

Section 208.24 builds a chain. The manufacturer must get FDA approval of the guide, then supply guides, or the means to print them, in sufficient numbers to distributors and dispensers. Distributors pass them along with each shipment. The container label must tell the pharmacist to provide a guide to each patient and say how it is provided. At the end of the chain, the dispenser must hand a guide "directly to each patient (or to the patient's agent)" when the product is dispensed.

FDA's patient labeling page³ says the guide is given in paper form by default, though a patient may also request electronic delivery. Section 208.26(b) adds one exception with a limit on it. A prescriber may direct that a particular patient not receive a guide if there are significant concerns about its effect, but the dispenser must still provide one to any patient who asks.

Setting changes the picture. FDA's November 2011 guidance⁴ on distribution says the agency intends to exercise enforcement discretion when a drug is dispensed to a health professional who gives it to a patient in a hospital, clinic, infusion center or dialysis unit. Even then, a guide must be provided if the patient asks, the first time the drug is dispensed in an outpatient clinic, the first time it is dispensed in any outpatient setting after the guide is materially changed, and whenever a risk program called a REMS requires it. For a prescription filled at a retail pharmacy and taken home, FDA's table in the guidance says the guide must be provided each time the drug is dispensed.

Patient package inserts and other leaflets

A patient package insert, often titled "Patient Information," is a different document. FDA requires PPIs for only two groups, oral contraceptives⁶ and estrogen-containing products⁷, and those must be dispensed with each prescription. The estradiol tablet label GxRadar checked carries one. For every other drug, FDA says manufacturers submit PPIs voluntarily and FDA approves them, "but their distribution is not mandated." Labels for atorvastatin and metformin on DailyMed include such leaflets.

Instructions for Use, approved by FDA for drugs with complicated or detailed patient-use steps, cover preparation, administration, storage and disposal. The leaflet most pharmacies staple to the bag, next to the prescription label, is often none of these. FDA calls it consumer medication information, written by someone other than the drug company, and says FDA "does not review or approve CMI."

A few questions sort out which documents a prescription should come with:

• Does this medicine have an FDA-approved Medication Guide or patient package insert, and is it in the bag?
• Has the guide changed since my last fill?
• Can I get the guide electronically as well as on paper?
• Where in the full label can I read the prescribing information it summarizes?

Every one of these documents is posted on DailyMed with the label it belongs to, and our guide to looking up a drug on DailyMed shows where each sits. Some carry disposal instructions that take priority over FDA's general advice, as our disposal guide explains, and the pharmacist script has wording for the counter.

The one-page proposal

On May 31, 2023, FDA proposed a new kind of Medication Guide called Patient Medication Information⁹ (88 FR 35694). It would be a one-page document with standardized format and content, required for prescription drugs used, dispensed or administered on an outpatient basis. The proposal says PMI "would replace the current Medication Guides and Patient Package Inserts," and FDA's analysis projected that most products that previously had Medication Guides would have approved PMI two years after a final rule took effect.

The comment period closed Nov. 27, 2023. In its July 2026 notice, FDA said comments on the existing guides had been added to the rulemaking docket, FDA-2019-N-5959, "for continued consideration." A search of the Federal Register found no final PMI rule as of Nov. 3, 2026.